24 March 2017

genedrive plc: Notice of Interim Results


genedrive plc (LSE: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ended 31 December 2016 on Thursday, 30 March 2017.

For further details please contact:

genedrive plc
David Budd: CEO
+44 (0)161 989 0245
Matthew Fowler: Finance Director

Peel Hunt LLP
James Steel
+44 (0)207 418 8900
Oliver Jackson

Consilium Strategic Communications
Chris Gardner  
+44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com 

Notes to editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

Further details can be found at: www.genedriveplc.com and www.genedrive.com.


Back to previous page